Skip to main content

Table 1 Anthropometric measurements, metabolism and body fat distribution of patients in different groups

From: Correlation between serum uric acid and body fat distribution in patients with MAFLD

Items

normouricemic

MAFLD with normal SUA

MAFLD with high SUA

P values

 

N = 81

N = 267

N = 137

 

Age (years)

40.58 ± 11.55

42.50 ± 11.03

34.33 ± 10.04

 < 0.000b,c

Weight (kg)

63.01 ± 11.72

74.37 ± 11.67

85.45 ± 15.71

 < 0.000a,b,c

BMI (kg/m2)

24.14 ± 3.15

27.67 ± 3.85

30.49 ± 4.76

 < 0.000a,b,c

WHR

0.87 (0.84,0.92)

0.93 (0.88,0.97)

0.95 (0.89,0.99)

 < 0.000a,b

SBP (mmHg)

119 (107.75,132.00)

130.00 (122.00,140.00)

132.00 (121.00,142.00)

 < 0.000a,b

DBP (mmHg)

75.67 ± 12.27

80.89 ± 10.43

82.57 ± 10.55

 < 0.000a,b

Ogirt 0 min (uU/mL)

8.17 (4.39,11.93)

14.62 (9.29,22.33)

22.23 (15.35,35.53)

 < 0.000a,b,c

Ogirt AUC

3988.80 (2039.25, 7219.35)

7390.20 (2890.05,13,046.40)

11,586.45 (5683.50,20,019.50)

 < 0.000b,c

ALT (U/L)

18.00 (13.00,24.00)

26.00 (19.00,40.00)

43.00 (25.00,82.50)

 < 0.000a,b,c

AST (U/L)

18.00 (14.00,22.00)

20.00 (16.00,29.00)

29.00 (19.00,52.00)

 < 0.000a,b,c

TC (mmol/L)

4.92 (4.38,5.69)

5.04 (4.38,5.87)

5.29 (4.65,6.25)

0.114

TG (mmol/L)

1.40 (0.93,2.25)

1.93 (1.43,3.41)

2.49 (1.72,4.26)

 < 0.000a,b,c

LDL-c (mmol/L)

2.63 (2.22,3.21)

2.70 (2.15,3.21)

2.74 (2.20,3.37)

0.804

HDL-c (mmol/L)

1.19 ± 0.28

1.08 ± 0.26

1.05 ± 0.24

0.001a,b

SUA (μmol/L)

281.15 ± 72.52

322.84 ± 59.97

502.66 ± 75.94

 < 0.000b,c

VAT (cm2)

61.00 (40.50,79.00)

95.00 (76.00,114.00)

112.00 (92.00,137.00)

 < 0.000a,b,c

SAT (cm2)

155.51 ± 73.25

213.52 ± 76.86

263.98 ± 85.00

 < 0.000a,b,c

NFS

-1.77 ± 2.27

-1.86 ± 1.86

-2.25 ± 2.23

0.163

FIB-4

0.79 (0.52,1.19)

0.79 (0.56,1.19)

0.70 (0.46,1.16)

0.194

HOMA-IR

1.44 (1.18796,2.75748)

2.80 (1.36,6.04)

2.34 (1.21,5.93)

0.011a

CAP

202.86 ± 23.77

301.38 ± 37.24

316.70 ± 39.18

 < 0.000a,b

FFA (mmol/L)

0.45 ± 0.28

0.56 ± 0.23

0.64 ± 0.22

0.001a,b

Adipo-IR

2.42 (0.10,4.3407)

6.53 (3.14,11.69)

12.72 (5.98,21.93)

 < 0.000a,b,c

metabolic syndrome (%, n)

45.70 (37.00)

64.00 (171.00)

73.00 (100.00)

0.17

Total body fat (%)

38.05 (35.78,40.40)

42.10 (38.35,45.65)

40.90 (35.40,45.00)

0.035a

Upper limbs fat mass (g)

3068.86 ± 812.91

3391.38 ± 775.40

3727.95 ± 682.82

0.018b

Thighs fat mass (g)

7383.50 (6082.00,8327.25)

8607.50 (6914.75,10,142.50)

9422.00 (7489.00,12,372.00)

0.017b

trunk fat mass (g)

12,534.00 (11,860.50,14,263.25)

17,726.00 (15,563.00,20,313.80)

20,288.00 (17,032.00,24,411.00)

 < 0.000a,b,c

Android (g)

1900.50 (1661.50,2172.75)

2870.50 (2535.75,3382.75)

3434.00 (2710.00,4151.00)

 < 0.000a,b,c

Gynoid (g)

4052.50 (3549,00,4263.00)

4704.00 (4112.25,5501.00)

5165.00 (4013.00,6522.00)

0.005b

Total Body fat (g)

25,165.93 ± 6476.60

31,210.53 ± 5594.23

36,288.14 ± 8080.05

 < 0.000a,b,c

  1. Normally distributed data are represented as the mean ± standard deviation (SD), while data showing skewed distribution are represented as the median (interquartile range)
  2. Abbreviations: BMI body mass index, WHR waist hip ratio, SBP systolic blood pressure, DBP diastolic blood pressure, Ogirt oral glucose insulin releasing test, Ogirt AUC area under Ogirt curve, ALT alanine aminotransferase, AST aspartate aminotransferase, TC total cholesterol, TG triglyceride, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, SUA serum uric acid, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, NFS Non-alcoholic fatty liver disease fibrosis score, FIB-4 Fibrosis-4 score, HOMA-IR homeostasis model assessment of insulin resistance, CAP Controlled attenuation parameters, FFA free fatty acid, Adipo-IR adipose tissue insulin resistance
  3. aindicates that there is a statistically significant difference between normouricemic and MAFLD with normal SUA
  4. bindicates that there is a statistically significant difference between normouricemic and MAFLD with high SUA
  5. cindicates that there is a statistically significant difference between MAFLD with normal SUA and MAFLD with high SUA